2024
Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases
Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.Peer-Reviewed Original ResearchColorectal cancer peritoneal metastasesCRC PMPeritoneal metastasisColorectal cancerIntra-tumor heterogeneitySystemic regimensTherapeutic targetAmerican Association for Cancer Research annual meetingsPrognosis of peritoneal metastasisResistant to systemic chemotherapyPlasma-peritoneal barrierOncological surgical resectionColorectal cancer patientsSystemic chemotherapySurgical resectionPalliative surgerySystemic therapyAntineoplastic therapyPotential therapeutic targetExploratory laparotomyTranscoelomic metastasisPoor prognosisFFPE tissue samplesSynchronous PMPoor responseOncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.
Zhao J, Huang K, Chia D, Law J, Tan A, So J, Tan P, Sundar R. Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis. Journal Of Clinical Oncology 2024, 42: 392-392. DOI: 10.1200/jco.2024.42.3_suppl.392.Peer-Reviewed Original ResearchPeritoneal metastasisPrimary tumorWhole-exome sequencingARID1A mutationsGastric cancerMedian follow-up durationGS tumorsPrimary tumors of patientsMetachronous peritoneal metastasesAssociated with PMFollow-up durationGastric cancer tumorsPoor survival outcomesPrimary GC tumorsMetachronous PMAdvanced tumorsCDH1 mutationsSurgical resectionOncogenic aberrationsSurvival outcomesClinical outcomesPoor prognosisFollowed-upProspective cohortRHOA mutations
2023
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.Peer-Reviewed Original ResearchConceptsNeutrophil-lymphocyte ratioRoyal Marsden HospitalPhase I studyPhase I clinical trialPoor ECOG statusPre-treated patientsPrimary tumor sitePhase I populationLonger-term survivalECOG statusPrognostic factorsPrognostic scoreRetrospective reviewTumor siteAsian patientsSolid tumorsClinical outcomesPoor prognosisBackgroundPatient selectionPrognostic abilityPrognostic modelPatientsPrognosisIncreased scoresScores
2022
Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis
Chan J, Zhang B, Chew X, Salhi A, Kwok Z, Lim C, Desi N, Subramaniam N, Siemens A, Kinanti T, Ong S, Sanchez-Mejias A, Ly P, An O, Sundar R, Fan X, Wang S, Siew B, Lee K, Chong C, Lieske B, Cheong W, Goh Y, Fam W, Ooi M, Koh B, Iyer S, Ling W, Chen J, Yoong B, Chanwat R, Bonney G, Goh B, Zhai W, Fullwood M, Wang W, Tan K, Chng W, Dan Y, Pitt J, Roca X, Guccione E, Vardy L, Chen L, Gao X, Chow P, Yang H, Tay Y. Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis. Nature Cell Biology 2022, 24: 928-939. PMID: 35618746, PMCID: PMC9203280, DOI: 10.1038/s41556-022-00913-z.Peer-Reviewed Original ResearchConceptsUntranslated regionProtein-coding alterationsPost-transcriptional regulationAnti-cancer therapeuticsMammalian genesAlternative polyadenylationPan-cancer landscapeSplicing studiesAntisense oligonucleotide-mediated inhibitionUTR variantsDysregulation eventsSplicingOncogenic functionActivated oncogenesOncogene expressionMessenger RNAOncogeneTumor progressionPolyadenylationPoor prognosisHepatocellular carcinomaUpregulationColon adenocarcinomaGenesRNA
2017
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Sundar R, Hong D, Kopetz S, Yap T. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery 2017, 7: 558-560. PMID: 28576843, PMCID: PMC5458523, DOI: 10.1158/2159-8290.cd-17-0087.Commentaries, Editorials and Letters